3C Therapeutics
San Diego, United States· Est.
A private biotech leveraging antibody‑guided protein degraders for universal targeted protein degradation.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A private biotech leveraging antibody‑guided protein degraders for universal targeted protein degradation.
OncologyImmunologyRare Diseases
Technology Platform
Degrader‑Antibody Conjugate (DAC) platform that links monoclonal antibodies to intracellular protein degraders for targeted, catalytic protein degradation.
Opportunities
The DAC platform can unlock therapeutic access to intracellular targets across multiple disease areas, offering a differentiated approach to the growing TPD market.
Risk Factors
Technical challenges in achieving efficient intracellular release and safety of antibody‑guided degraders, plus competition from established degrader developers.
Competitive Landscape
Competes with PROTAC and molecular glue developers (e.g., Arvinas, C4 Therapeutics) and antibody‑drug conjugate platforms, differentiating through catalytic intracellular degradation rather than payload delivery.